| Name | Title | Contact Details |
|---|---|---|
Rick Scruggs |
Chief Operating Officer | Profile |
Serge Zwikker |
Director of Information Technology | Profile |
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention of counterfeiting and diversion. We have manufacturing facilities in Hawaii, engineering offices in California, and business development offices in Pennsylvania, Texas and Hong Kong. TruTag`s early technology research was funded in part by the U.S. Army Medical Research division. The company is supported by venture capital firms and strategic corporate investors.
Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.
Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.
Taisho Pharmaceutical California is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.